Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in treating
aesthetic and therapeutic conditions, today announced that Mark
Foley has been appointed to Revance’s Board of Directors, effective
September 5, 2017.
Mr. Foley most recently served as Chairman, President and CEO of
ZELTIQ* Aesthetics (ZLTQ). He brings more than 25 years of
operational and investment experience in the healthcare arena, and
earlier this year led the sale of ZELTIQ to Allergan for $2.5
billion.
“Revance is honored to add Mark Foley to our Board of Directors.
Mark is a healthcare industry visionary, having significant
leadership and commercialization expertise,” said Dan Browne,
President and Chief Executive Officer at Revance. “With Mark’s
experience as Chairman, CEO and/or board member for a number of
aesthetic and medical device companies, he brings a broad and
balanced perspective across diverse disciplines -- from product
positioning and commercial operations to strategies that drive
company growth and generate significant shareholder value.”
“I am excited to join Revance’s Board of Directors and look
forward to collaborating with the other members of the Board, as
well as Revance’s leadership, to bring the first distinctly new
neuromodulator to market,” said Mr. Foley. “I believe my experience
– particularly with ZELTIQ’s CoolSculpting* franchise – can help
Revance build a successful aesthetics business and fuel its efforts
in the commercialization of a variety of therapeutic indications.
Revance’s neuromodulation platform is uniquely positioned to
address major current unmet needs and significantly grow the
market.”
Mr. Foley is Managing Director of RWI Ventures, a venture
capital firm focused on life sciences, networking, semiconductor
and software investments. Previously, he was Chairman, President
and CEO of ZELTIQ Aesthetics (ZLTQ), serving from 2012 through the
company’s acquisition by Allergan (AGN). During his tenure, he led
ZELTIQ’s growth from $68 million in annual revenue in 2012 to over
$350 million in 2016. Prior to ZELTIQ, Mr. Foley held a variety of
senior operating roles in large public companies and venture-backed
startups, including U.S. Surgical Corporation, Guidant Corporation,
Devices for Vascular Intervention (acquired by Eli Lilly), Perclose
(acquired by Abbott) and Ventrica (acquired by Medtronic) where he
was the founder and CEO. He is a board member at Glaukos (GKOS) and
also serves as Chairman of ULab and HintMD. Mr. Foley received a
B.A. degree from the University of Notre Dame.
Concurrent with Mr. Foley’s appointment, Ron Eastman will step
down from the Revance Board of Directors. "Since joining our board
in 2009, Ron guided us from our early development stage, through
the initial public offering and now into pre-commercialization
activities for our neuromodulator programs," said Mr. Browne. “He
brought extensive and valuable corporate governance expertise,
board oversight and operational experience. Ron has been a great
resource for me personally, and I thank him for his many years of
service to Revance."
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance’s science is based upon a
proprietary peptide technology, which when combined with active
drug molecules, may help address current unmet needs. Revance’s
initial focus is on developing daxibotulinumtoxinA, the company’s
highly purified botulinum toxin, for a broad spectrum of aesthetic
and therapeutic indications, including facial wrinkles and muscle
movement disorders.
The company’s lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis, with the
potential to be the first long-acting neuromodulator. The company
holds worldwide rights to RT002 injectable and RT001 topical and
the pharmaceutical uses of its proprietary peptide technology
platform. More information on Revance may be found
at www.revance.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to: statements about our business
strategy, our investigational drug product candidates, expected
efficacy of our drug product candidates, clinical development,
goals and market for our anticipated products, plans and prospects
and statements about potential benefits of our drug product
candidates and our technologies.
Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially from our expectations. These risks and uncertainties
include, but are not limited to: the outcome, cost, and timing of
our product development activities and clinical trials; the
uncertain clinical development process, including the risk that
clinical trials may not have an effective design or generate
positive results; our ability to obtain and maintain regulatory
approval of our drug product candidates; our ability to obtain
funding for our operations; our plans to research, develop, and
commercialize our drug product candidates; our ability to achieve
market acceptance of our drug product candidates; unanticipated
costs or delays in research, development, and commercialization
efforts; the applicability of clinical study results to actual
outcomes; the size and growth potential of the markets for our drug
product candidates; our ability to successfully commercialize our
drug product candidates and the timing of commercialization
activities; the rate and degree of market acceptance of our drug
product candidates; our ability to develop sales and marketing
capabilities; the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; our
ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks.
Detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange Commission (the
"SEC"), including factors described in the section entitled "Risk
Factors" of our quarterly report on Form 10-Q filed August 4, 2017.
These forward-looking statements speak only as of the date hereof.
Revance disclaims any obligation to update these forward-looking
statements.
“Revance Therapeutics” and the Revance logo are
registered trademarks of Revance Therapeutics, Inc.
*”ZELTIQ” and “CoolSculpting” are registered
trademarks of ZELTIQ Aesthetics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170906005643/en/
Investors:Revance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami
Bavishi, 212-213-0006abavishi@burnsmc.comorTrade Media, Inc.:Nadine
Tosk, 504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2024 to May 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From May 2023 to May 2024